Genetic ablation or chemical inhibition of phosphatidylcholine transfer protein attenuates diet-induced hepatic glucose production

Hepatology

Volumn 54, Issue 2, 2011, Pages 664-674

  Shishova, Ekaterina Y ^a   Stoll, Janis M ^a   Ersoy, Baran A ^a   Shrestha, Sudeep ^a   Scapa, Erez F ^b   Li, Yingxia ^a   Niepel, Michele W ^a   Su, Ya ^c   Jelicks, Linda A ^c   Stahl, Gregory L ^a   Glicksman, Marcie A ^d   Gutierrez Juarez, Roger ^c   Cuny, Gregory D ^d   Cohen, David E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; LDN 193188; LECITHIN TRANSFER PROTEIN; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID BINDING PROTEIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ATTENUATION; BINDING SITE; CELL CULTURE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID DIET; LIVER CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; THERMOSTABILITY;

ANIMALS; DIET; GLUCOSE; LIVER; MICE; PHOSPHOLIPID TRANSFER PROTEINS;

EID: 79960726770     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24393     Document Type: Review

References (33)

1. Kanno K, Wu MK, Scapa EF, Roderick SL, Cohen DE. Structure and function of phosphatidylcholine transfer protein (PC-TP)/StarD2. Biochim Biophys Acta 2007; 1771: 654-662.
2. Wirtz KW. Phospholipid transfer proteins. Annu Rev Biochem 1991; 60: 73-99.
3. Roderick SL, Chan WW, Agate DS, Olsen LR, Vetting MW, Rajashankar KR, et al. Structure of human phosphatidylcholine transfer protein in complex with its ligand. Nat Struct Biol 2002; 9: 507-511.
4. Ponting CP, Aravind L. START: a lipid-binding domain in StAR, HD-ZIP and signalling proteins. Trends Biochem Sci 1999; 24: 130-132.
5. Kang HW, Wei J, Cohen DE. PC-TP/StARD2: of membranes and metabolism. Trends Endocrinol Metab 2010; 21: 449-456.
6. Scapa EF, Pocai A, Wu MK, Gutierrez-Juarez R, Glenz L, Kanno K, et al. Regulation of energy substrate utilization and hepatic insulin sensitivity by phosphatidylcholine transfer protein/StarD2. FASEB J 2008; 22: 2579-2590.
7. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010; 375: 2267-2277.
8. Dolley G, Berthier MT, Lamarche B, Despres JP, Bouchard C, Perusse L, et al. Influences of the phosphatidylcholine transfer protein gene variants on the LDL peak particle size. Atherosclerosis 2007; 195: 297-302.
9. Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am 2006; 35: 491-510.
10. Pan HJ, Agate DS, King BL, Wu MK, Roderick SL, Leiter EH, et al. A polymorphism in New Zealand inbred mouse strains that inactivates phosphatidylcholine transfer protein. FEBS Lett 2006; 580: 5953-5958.
11. Wu MK, Hyogo H, Yadav S, Novikoff PM, Cohen DE. Impaired response of biliary lipid secretion to a lithogenic diet in phosphatidylcholine transfer protein-deficient mice. J Lipid Res 2005; 46: 422-431.
12. Hyogo H, Roy S, Paigen B, Cohen DE. Leptin promotes biliary cholesterol elimination during weight loss in ob/ob mice by regulating the enterohepatic circulation of bile salts. J Biol Chem 2002; 277: 34117-34124.
13. Shoda J, Oda K, Suzuki H, Sugiyama Y, Ito K, Cohen DE, et al. Etiologic significance of defects in cholesterol, phospholipid, and bile acid metabolism in the liver of patients with intrahepatic calculi. Hepatology 2001; 33: 1194-1205.
14. Barac-Nieto M, Gupta RK. Use of proton MR spectroscopy and MR imaging to assess obesity. J Magn Reson Imaging 1996; 6: 235-238.
15. Ilany J, Bilan PJ, Kapur S, Caldwell JS, Patti ME, Marette A, et al. Overexpression of Rad in muscle worsens diet-induced insulin resistance and glucose intolerance and lowers plasma triglyceride level. Proc Natl Acad Sci U S A 2006; 103: 4481-4486.
16. Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci U S A 2007; 104: 12861-12866.
17. Ayala JE, Samuel VT, Morton GJ, Obici S, Croniger CM, Shulman GI, et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech 2010; 3: 525-534.
18. Okamoto H, Obici S, Accili D, Rossetti L. Restoration of liver insulin signaling in Insr knockout mice fails to normalize hepatic insulin action. J Clin Invest 2005; 115: 1314-1322.
19. Kanno K, Wu MK, Agate DA, Fanelli BK, Wagle N, Scapa EF, et al. Interacting proteins dictate function of the minimal START domain phosphatidylcholine transfer protein/StarD2. J Biol Chem 2007; 282: 30728-30736.
20. Wagle N, Xian J, Shishova EY, Wei J, Glicksman MA, Cuny GD, et al. Small-molecule inhibitors of phosphatidylcholine transfer protein/StarD2 identified by high-throughput screening. Anal Biochem 2008; 383: 85-92.
21. Soccio RE, Breslow JL. StAR-related lipid transfer (START) proteins: mediators of intracellular lipid metabolism. J Biol Chem 2003; 278: 22183-22186.
22. Olayioye M, Hoffmann P, Pomorski T, Armes J, Simpson R, Kemp B, et al. The phosphoprotein StarD10 is overexpressed in breast cancer and cooperates with ErbB receptors in cellular transformation. Cancer Res 2004; 64: 3538-3544.
23. Olayioye MA, Vehring S, Muller P, Herrmann A, Schiller J, Thiele C, et al. StarD10, a START domain protein overexpressed in breast cancer, functions as a phospholipid transfer protein. J Biol Chem 2005; 280: 27436-27442.
24. Angeletti S, Rena V, Nores R, Fretes R, Panzetta-Dutari GM, Genti-Raimondi S. Expression and localization of StarD7 in trophoblast cells. Placenta 2008; 29: 396-404.
25. Horibata Y, Sugimoto H. StarD7 mediates the intracellular trafficking of phosphatidylcholine to mitochondria. J Biol Chem 2010; 285: 7358-7365.
26. Montalto MC, Collard CD, Buras JA, Reenstra WR, McClaine R, Gies DR, et al. A keratin peptide inhibits mannose-binding lectin. J Immunol 2001; 166: 4148-4153.
27. Biddinger SB, Kahn CR. From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol 2006; 68: 123-158.
28. Taguchi A, White MF. Insulin-like signaling, nutrient homeostasis, and life span. Annu Rev Physiol 2008; 70: 191-212.
29. Miller RA, Birnbaum MJ. An energetic tale of AMPK-independent effects of metformin. J Clin Invest 2010; 120: 2267-2270.
30. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
31. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
32. Liu B, Turley SD, Burns DK, Miller AM, Repa JJ, Dietschy JM. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse. Proc Natl Acad Sci U S A 2009; 106: 2377-2382.
33. Van Paridon PA, Gadella TWJ, Somerharju PJ, Wirtz KWA. On the relationship between the dual specificity of the bovine brain phosphatidylinositol transfer protein and membrane phosphatidylinositol levels. Biochim Biophys Acta 1987; 903: 68-77.